{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033684","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.683468+00:00","generated_at":"2026-06-04T22:28:45.572411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Liquidia FY2023 net loss $78.5M ($1.21/sh); patent victory clears path for YUTREPIA launch","bullets":["Net loss $78.5M ($1.21/sh) vs $41.0M ($0.67/sh) in FY2022; R&D spend rose 122% to $43.2M.","Cash $83.7M at Dec 31, 2023; raised $100M in Jan 2024 via equity placement and debt amendment.","Federal Circuit denied United Therapeutics' rehearing request, upholding invalidity of '793 Patent; injunction removal awaited.","YUTREPIA ready for launch in PAH and PH-ILD after Tyvaso exclusivity expires March 31, 2024 and injunction lifted.","L606 Phase 3 PH-ILD study planned by end-2024; ASCENT enrollment (60 patients) ongoing with interim data expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033684","json":"https://secwatch.observer/filing/0001104659-24-033684.json","markdown":"https://secwatch.observer/filing/0001104659-24-033684.md","text":"https://secwatch.observer/filing/0001104659-24-033684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/tm248678d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:28:45.572411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a01f1a365dd70a32b27d2b43a43e41c82e123248","claim":"Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.","evidence_excerpt":"$25.0 million. HCRx has now invested $67.5 million in non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the year ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2023"},{"label":"Revenue","value":"$17.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}